Riskpilot← Back to searchSign inGet full accessMediracer Oy
OYActiveY-tunnus 1769016-7Kasarmintie 13Manufacture of medical and dental instruments and supplies · NACE 3250Est. 2002— employeeswww.mediracer.com
Revenue 2024
EUR 167K
-41% vs 2023
EBITDA margin
-52.5%
-1054% vs 2023
Equity ratio
-401.5%
Financial strength
Net profit 2024
EUR -158K
-113% vs 2023
| Revenue | EUR 167K | -41% |
| EBITDA | EUR -87K | -1054% |
| Net profit | EUR -158K | -113% |
| Total assets | EUR 286K | -30% |
| Equity | EUR -1,1M | -16% |
| Employees | — | — |
Legal name
Mediracer Oy
Y-tunnus number
1769016-7
Legal form
Osakeyhtiö
NACE code
3250 · Manufacture of medical and dental instruments and supplies
Founded
10. kesäkuuta 2002
Share capital
EUR 297 150
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin
Company purpose
Yhtiön toimialana on hyvinvointiteknologian, sairaalateknologian ja telelääketieteeseen liittyvien laitteiden sekä järjestelmien että palveluiden kehittäminen uusmediaa hyödyntäen. Mobiilin teknologian kehittäminen diagnostisiin tutkimuslaitteisiin ihmisestä ihon pinnalta mitattaville neurofysiologisille ja fysiologisille ilmiölle (PDS-laitteet, Portable Diagnostic System). Valmistaminen ja myynti erityisesti kansainvälisille markkinoille sekä alaan liittyvä tuontitoiminta. Yhtiön toimialana on myös lääketieteellisen tutkimustyön tuloksena syntyvien laite- ja palveluideoiden tuotteistaminen sekä näiden vaatimien kliinisten testien suorittaminen tai järjestäminen.
Address
Kasarmintie 13
Phone
+358458992626
Email
info@mediracer.com
Website
www.mediracer.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 208 | 207 | 199 | 283 | 167 |
| Staff expenses | −202 | −103 | −95 | −104 | −80 |
| EBITDA | −260 | 16 | −29 | −8 | −87 |
| Depreciation & amort. | −50 | −54 | −58 | −60 | −60 |
| EBIT | −310 | −37 | −87 | −68 | −148 |
| Net financials | −224 | −1 | −7 | −7 | −9 |
| Profit before tax | −534 | −39 | −93 | −74 | −157 |
| Tax | −0 | −0 | −0 | −0 | 1 |
| Net profit | −534 | −39 | −93 | −74 | −158 |
| Item | 2019 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 603 | 508 | 428 | 408 | 286 |
| Equity | −512 | −822 | −916 | −990 | −1 148 |
| Long-term debt | 862 | 1 191 | 1 191 | 1 219 | 1 238 |
| Short-term debt | 254 | 140 | 153 | 179 | 196 |
| Total debt | 1 116 | 1 331 | 1 344 | 1 398 | 1 434 |
EBITDA margin
-52.5%
This company
15.8%
Market median
-432% vs market
20192024
Equity ratio
-401.5%
This company
38.2%
Market median
-1151% vs market
20192024
Return on equity
-15815200.0%
This company
18.4%
Market median
-85952274% vs market
20192024
Net profit margin
-94.9%
This company
8.1%
Market median
-1272% vs market
20192024
Asset turnover
0.58×
This company
1.12×
Market median
-48% vs market
20192024
Debt / equity
1.25×
This company
0.62×
Market median
-102% vs market
20192024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2019Filed via PRH / YTJ · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KA Chief Executive Officer | Chief Executive Officer | 2024 |
| Former (2) | ||
SS | Audit | 2012 – 2023 |
GM Chief Executive Officer | Chief Executive Officer | 2018 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Chairperson | 2023 | |
| Board of Directors | 2023 | |
| Board of Directors | 2023 | |
| Board of Directors | 2018 | |
| Board of Directors | 2023 | |
| Former (3) | ||
| Board of Directors | 2021 – 2023 | |
| Chairperson | 2021 – 2023 | |
| Board of Directors | 2018 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 85.4% | 85.4% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Head Medical Oy
Mediracer Oy Board members of Mediracer Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Katja Annele Findlay | Chief Executive Officer | 0 companies |
| Sami Seppo Sakari Posti | Audit | 0 companies |
| Georg Meissner | Chief Executive Officer | 0 companies |
| Veli-Pekka Sipola | Board of Directors | 0 companies |
| Jari Pekka Vallström | Chairperson | 0 companies |
| Harri Tapio Lilja | Chairperson | 0 companies |
| Pentti Kalervo Manninen | Board of Directors | 0 companies |
| Janne Kari Kalevi Heino | Board of Directors | 0 companies |
| Usko Elias Juhani Huuskonen | Board of Directors | 0 companies |
| Lauri Jaakko Antila | Board of Directors | 0 companies |
| Heikki Tapani Johansson | Board of Directors | 0 companies |